Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.83)
# 428
Out of 4,476 analysts
400
Total ratings
52.4%
Success rate
20.1%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Reiterated: Buy | $42 | $13.28 | +216.27% | 26 | Jun 25, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $250 | $146.76 | +70.35% | 9 | Jun 24, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $50 → $40 | $14.12 | +183.29% | 10 | Jun 1, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Initiated Coverage: Buy | $35.50 | $9.53 | +272.49% | 1 | May 21, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $50 → $56 | $57.80 | -3.11% | 10 | May 12, 2026 | |
| TRVI Trevi Therapeutics | Rated: Buy | $18 → $30 | $17.93 | +67.32% | 24 | May 8, 2026 | |
| MLYS Mineralys Therapeutics | Maintained: Buy | $52 | $27.69 | +87.79% | 13 | May 7, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $230 | $243.47 | -5.53% | 41 | May 6, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Hold | $55 | $48.05 | +14.48% | 31 | May 6, 2026 | |
| EOLS Evolus | Maintained: Buy | $17 | $6.90 | +146.38% | 26 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $95 | $37.44 | +153.74% | 23 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $230 → $255 | $319.55 | -20.20% | 7 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $15 | $3.91 | +283.63% | 17 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 | $53.45 | +68.38% | 8 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 | $11.20 | +150.00% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.16 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.125 | - | 18 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $0.7713 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2,250.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.02 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $7.72 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21.30 → $19.88 | $6.96 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.008 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $3.22 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $2.11 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $11.02 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $5.54 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $90.21 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $7.28 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $32.96 | n/a | 1 | Oct 18, 2011 |
REGENXBIO
Jun 25, 2026
Reiterated: Buy
Price Target: $42
Current: $13.28
Upside: +216.27%
Palvella Therapeutics
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $146.76
Upside: +70.35%
Oculis Holding AG
Jun 1, 2026
Maintained: Buy
Price Target: $50 → $40
Current: $14.12
Upside: +183.29%
Eupraxia Pharmaceuticals Inc.
May 21, 2026
Initiated Coverage: Buy
Price Target: $35.50
Current: $9.53
Upside: +272.49%
MBX Biosciences
May 12, 2026
Reiterated: Buy
Price Target: $50 → $56
Current: $57.80
Upside: -3.11%
Trevi Therapeutics
May 8, 2026
Rated: Buy
Price Target: $18 → $30
Current: $17.93
Upside: +67.32%
Mineralys Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $52
Current: $27.69
Upside: +87.79%
Jazz Pharmaceuticals
May 6, 2026
Reiterated: Buy
Price Target: $230
Current: $243.47
Upside: -5.53%
Supernus Pharmaceuticals
May 6, 2026
Maintained: Hold
Price Target: $55
Current: $48.05
Upside: +14.48%
Evolus
May 5, 2026
Maintained: Buy
Price Target: $17
Current: $6.90
Upside: +146.38%
Apr 30, 2026
Maintained: Buy
Price Target: $95
Current: $37.44
Upside: +153.74%
Apr 27, 2026
Reiterated: Buy
Price Target: $230 → $255
Current: $319.55
Upside: -20.20%
Mar 31, 2026
Maintained: Buy
Price Target: $17 → $15
Current: $3.91
Upside: +283.63%
Feb 27, 2026
Maintained: Buy
Price Target: $90
Current: $53.45
Upside: +68.38%
Jan 15, 2026
Maintained: Buy
Price Target: $28
Current: $11.20
Upside: +150.00%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.16
Upside: -
Dec 16, 2025
Rated: Hold
Price Target: n/a
Current: $0.125
Upside: -
Apr 1, 2025
Maintained: Buy
Price Target: $8
Current: $0.7713
Upside: n/a
Jan 8, 2025
Maintained: Buy
Price Target: n/a
Current: $2,250.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $2.02
Upside: n/a
Aug 30, 2023
Maintained: Hold
Price Target: $11
Current: $7.72
Upside: n/a
Nov 3, 2022
Maintained: Buy
Price Target: $21.30 → $19.88
Current: $6.96
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.008
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $3.22
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $5
Current: $2.11
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $11.02
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $5.54
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $90.21
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $7.28
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $32.96
Upside: n/a